{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:19:14Z","timestamp":1772468354666,"version":"3.50.1"},"reference-count":76,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background\/Objectives: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare but life-threatening thrombotic microangiopathy in children. Secondary forms, occurring in association with immune dysregulation, autoimmune disease, or other triggers, are particularly challenging to diagnose and manage, and pediatric-specific data remain limited. This study aimed to describe the clinical characteristics, diagnostic pathways, and management of pediatric iTTP and to contextualize these findings within the recent literature. Methods: We conducted a retrospective case series of pediatric patients diagnosed with iTTP at a tertiary referral center, between November 2021 and January 2026. Clinical presentation, laboratory findings, including ADAMTS13 activity and ADAMTS13 inhibitors, associated conditions, treatment strategies, and outcomes were reviewed. In parallel, a narrative literature review was performed focusing on pediatric immune-mediated secondary TTP published over the past five years. Results: Four pediatric patients (three females, one male; median age 14 years) met inclusion criteria. All presented with severe thrombocytopenia and microangiopathic hemolytic anemia, accompanied by prominent neurologic manifestations in three cases. Severe ADAMTS13 activity deficiency (\u226410%) with positive inhibitors was documented in all patients. Secondary iTTP occurred in association with evolving systemic autoimmunity, systemic lupus erythematosus, common variable immunodeficiency, or without an identifiable trigger at presentation. High clinical probability scores facilitated early diagnosis. Management required plasma exchange, corticosteroids, and targeted and immunomodulatory therapy. Conclusions: Pediatric secondary iTTP is a heterogeneous condition that frequently presents with diagnostic ambiguity and severe neurologic involvement. Early recognition, prompt initiation of TTP-directed therapy, and comprehensive immunologic evaluation are critical for favorable outcomes. Case series combined with narrative reviews remain valuable for advancing understanding and optimizing individualized care in this rare pediatric disorder.<\/jats:p>","DOI":"10.3390\/children13030350","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:55:01Z","timestamp":1772463301000},"page":"350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Series and Literature Narrative Review of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Children"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-5479","authenticated-orcid":false,"given":"Leti\u021bia-Elena","family":"Radu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea Nicoleta","family":"\u0218erb\u0103nic\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-6620","authenticated-orcid":false,"given":"Andra Daniela","family":"Marcu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Maria","family":"Bic\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-5859","authenticated-orcid":false,"given":"Cristina Georgiana","family":"Jercan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Obri\u0219c\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana","family":"Gherghe","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Hemostasis Laboratory, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1042-753X","authenticated-orcid":false,"given":"Gabriela","family":"Droc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Anesthesiology and Intensive Care Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-5754","authenticated-orcid":false,"given":"Dana","family":"Tomescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Anesthesiology and Intensive Care Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-8190","authenticated-orcid":false,"given":"Anca","family":"Coli\u021b\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201dCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Pediatrics Department, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 Focused update of the ISTH guidelines for the diagnosis and management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/aob-22-29","article-title":"Immune thrombotic thrombocytopenic purpura: Pathogenesis and novel therapies: A narrative review","volume":"8","author":"Liu","year":"2023","journal-title":"Ann. Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/JBM.S464365","article-title":"A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura","volume":"15","author":"Du","year":"2024","journal-title":"J. Blood Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Snyder, M.R., and Maitta, R.W. (2025). Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura. Antibodies, 14.","DOI":"10.3390\/antib14010024"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2022.12.011","article-title":"Adolescent acquired thrombotic thrombocytopenic purpura: An analysis of the Pediatric Health Information System database","volume":"222","author":"Cohen","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.phoj.2024.01.005","article-title":"Thrombotic microangiopathy in children: Redefining hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and related disorders","volume":"9","author":"Manglani","year":"2024","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Karsenty, C.L., Kirk, E., Helber, H.L., Esquilin, J.M., Despotovic, J.M., and Grimes, A.B. (2022). Molecular diagnosis is vital to the accurate classification and management of thrombotic thrombocytopenic purpura in children. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.836960"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/vox.13738","article-title":"Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura","volume":"119","author":"Meiring","year":"2024","journal-title":"Vox Sang."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Saida, I.B., Maatouk, I., Toumi, R., Bouslama, E., Ismail, H.B., Salem, C.B., and Boussarsar, M. (2022). Acquired thrombotic thrombocytopenic purpura following inactivated COVID-19 vaccines: Two case reports and a short literature review. Vaccines, 10.","DOI":"10.22541\/au.164969104.48070542\/v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.htct.2023.01.001","article-title":"Thrombotic thrombocytopenic purpura and mushroom-shaped red blood cells secondary to COVID-19","volume":"46","author":"Borborema","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/bloodadvances.2024013488","article-title":"Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: The UK TTP Registry experience","volume":"8","author":"Taylor","year":"2024","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood-2025-1326","article-title":"Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: A scoping review of current evidence","volume":"146","author":"Salih","year":"2025","journal-title":"Blood Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jcph.1991","article-title":"Caplacizumab model-based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura","volume":"62","author":"Bergstrand","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chavaz, L., Cimasoni, L., Kremer Hovinga, J.A., Coppo, P., and Ansari, M. (2024). Caplacizumab as add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review. Front. Pediatr., 12.","DOI":"10.3389\/fped.2024.1448801"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjh.19035","article-title":"Bortezomib in relapsed\/refractory immune thrombotic thrombocytopenic purpura: A single-center retrospective cohort and systematic literature review","volume":"204","author":"Lee","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000524597","article-title":"Effect of blood groups on clinical presentations and treatment outcomes in immune thrombotic thrombocytopenic purpura patients with severe ADAMTS13 deficiency: A multi-center experience","volume":"50","author":"Sayin","year":"2023","journal-title":"Transfus. Med. Hemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102654","DOI":"10.1016\/j.rpth.2024.102654","article-title":"Characterization of bleeding in thrombotic thrombocytopenic purpura in the precaplacizumab era: A retrospective nationwide analysis","volume":"9","author":"Mahmoud","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bonifacio, M.A., Roselli, D., Schifone, C.P., Ricco, A., Vitucci, A., Aprile, L., Mariggio, M.A., and Ranierri, R.F. (2023). A long-term follow-up study in immune-mediated thrombotic thrombocytopenic purpura: What are the outcomes?. J. Clin. Med., 12.","DOI":"10.3390\/jcm12237305"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/jth.15406","article-title":"The standard of care for immune thrombotic thrombocytopenic purpura today","volume":"19","author":"Zheng","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: An international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.tru.2021.100062","article-title":"Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship","volume":"5","author":"Sukumar","year":"2021","journal-title":"Thromb. Update"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/13696998.2021.1922262","article-title":"Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura","volume":"24","author":"Pollissand","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aob-23-29","article-title":"Immune-mediated thrombotic thrombocytopenic purpura landscaping in Gulf countries: A real-world evidence study (ATHENA Study)","volume":"9","author":"Alsayegh","year":"2024","journal-title":"Ann. Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alkhunein, A., Albraikan, A., Alayed, M., Althaqafi, W., and Alharbi, M. (2023). Case report: Microangiopathic hemolytic anemia and thrombocytopenia in a child with Brucella infection. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1139622"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Angelucci, E., Artoni, A., Fianchi, L., Dovizio, M., Iacolare, B., Saragoni, S., and Degli Esposti, L. (2024). Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy. J. Clin. Med., 13.","DOI":"10.20944\/preprints202401.1937.v1"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mocanu, A., Bogos, R.A., Lazaruc, T.I., Cianga, A.L., Lupu, V.V., Ioniuc, I., Alecsa, M., Lupu, A., Ivanov, A.V., and Miron, I.C. (2023). Pitfalls of Thrombotic Microangiopathies in Children: Two Case Reports and Literature Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071228"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e28908","DOI":"10.1097\/MD.0000000000028908","article-title":"Successful treatment of thrombotic thrombocytopenic purpura with plasmapheresis and anti-CD20 antibodies in a patient with immune thrombocytopenia and systemic lupus erythematosus: Case report","volume":"101","author":"Jung","year":"2022","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.transci.2019.102717","article-title":"Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)","volume":"59","author":"Sabry","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lancellotti, S., Sacco, M., Tardugno, M., Ferretti, A., and De Cristofaro, R. (2023). Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093111"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/a-1171-0473","article-title":"Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura","volume":"40","author":"Roose","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Laghmouchi, A., Graca, N.A.G., and Voorberg, J. (2021). Emerging Concepts in Immune Thrombotic Thrombocytopenic Purpura. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.757192"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Joseph, A., Joly, B.S., Picod, A., Veyradier, A., and Coppo, P. (2023). The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093068"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Shrestha, N., Okpako, E., and Maitta, R.W. (2025). Thrombotic Thrombocytopenic Purpura in Pediatric Patients. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051038"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/JBM.S334689","article-title":"A Rare Association of Thrombotic Thrombocytopenic Purpura with Systemic Lupus Erythematosus in a Sudanese Woman: Case Report","volume":"12","author":"Ahmed","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2169\/internalmedicine.3939-19","article-title":"An Autopsy Case of Mixed Connective Tissue Disease Complicated by Thrombotic Thrombocytopenic Purpura","volume":"59","author":"Furuya","year":"2020","journal-title":"Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e22154","DOI":"10.1002\/jca.22154","article-title":"Therapeutic Plasma Exchange Management for a Pediatric Patient Presenting with Immune Thrombotic Thrombocytopenic Purpura in a Setting of Common Variable Immunodeficiency","volume":"39","author":"Budhipramono","year":"2024","journal-title":"J. Clin. Apher."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/JBM.S513578","article-title":"Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital Care","volume":"16","author":"Lawrie","year":"2025","journal-title":"J. Blood Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sukumar, S., L\u00e4mmle, B., and Cataland, S.R. (2021). Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030536"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tripiciano, C., Zangari, P., Montanari, M., Leone, G., Massella, L., Garaboldi, L., Massoud, M., Lancelotti, S., Stracchio, L., and Manno, E.C. (2021). Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated with Combined Therapy. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.743206"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5414\/CNCS111193","article-title":"Concomitant presentation of thrombotic thrombocytopenic purpura, immune thrombocytopenia, and autoimmune hemolytic anemia in a patient with newly diagnosed systemic lupus erythematosus","volume":"11","author":"Bruns","year":"2023","journal-title":"Clin. Nephrol. Case Stud."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13256-023-03762-y","article-title":"Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: A case report and review of the literature","volume":"17","author":"Lin","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"ref_43","first-page":"2676696","article-title":"A Case of Paediatric Anti-Glomerular Basement Membrane Disease Associated with Thrombotic Thrombocytopenic Purpura","volume":"2022","author":"McAllister","year":"2022","journal-title":"Case Rep. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/jpcc.jpcc_1_24","article-title":"Dengue fever presenting as thrombotic thrombocytopenic purpura in adolescent girl: A case report","volume":"11","author":"Gaur","year":"2024","journal-title":"J. Pediatr. Crit. Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.36401\/JIPO-24-2","article-title":"A Rare But Fatal Toxicity: Immune Checkpoint Inhibitor\u2013Related Acquired Thrombotic Thrombocytopenic Purpura","volume":"8","author":"Yikilmaz","year":"2025","journal-title":"J. Immunother. Precis Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kelen, K., Horv\u00e1th, O., Kis, \u00c9., Mikes, B., Sallay, P., Sinkovits, G., Proh\u00e1szka, Z., Szabo, A.J., and Reusz, G.S. (2023). Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814389"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Papakonstantinou, A., Kalmoukos, P., Mpalaska, A., Koravou, E.E., and Gavriilaki, E. (2024). ADAMTS13 in the New Era of TTP. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158137"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.3324\/haematol.2019.226068","article-title":"Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Graca","year":"2020","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s10020-025-01331-1","article-title":"Pathogenic cytokines in thrombotic microangiopathies: Molecular insights and therapeutic targets","volume":"31","author":"Obeagu","year":"2025","journal-title":"Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1111\/jth.15873","article-title":"Mechanisms of ADAMTS13 regulation","volume":"20","author":"DeYoung","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Demeter, F., Bihari, G., Vadicsku, D., Sinkovits, G., Kajd\u00e1csi, E., Horvath, L., Reti, M., Muller, V., Ivanyi, Z., and Gal, J. (2024). Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura\u2014Differences Compared to COVID-19. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810007"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Fodil, S., and Zafrani, L. (2022). Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041103"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"de Castro, J.T.d.S., Appenzeller, S., Colella, M.P., Yamaguti-Hayakawa, G., De Paula, E.V., Annichinno-Bizzachi, J., Cendes, F., Fabiano, R., and Orsi, F.A. (2022). Neurological manifestations in thrombotic microangiopathy: Imaging features, risk factors and clinical course. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272290"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dolin, H.H., and Maitta, R.W. (2024). Pathological Mechanisms and Novel Testing Methods in Thrombotic Thrombocytopenic Purpura. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030621"},{"key":"ref_55","first-page":"1","article-title":"Acquired thrombotic thrombocytopaenic purpura of an atypical, oligosymptomatic course in an adolescent girl","volume":"98","author":"Nowak","year":"2023","journal-title":"Pol. J. Paediatr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/ndt\/gfac034","article-title":"European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis","volume":"37","author":"Eller","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/bloodadvances.2024012608","article-title":"Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura","volume":"8","author":"Allen","year":"2024","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2335420","DOI":"10.1080\/16078454.2024.2335420","article-title":"Distinguishing thrombotic thrombocytopenic purpura from primary immune thrombocytopenia accompanied by anemia using the carbon monoxide breath test","volume":"29","author":"Tan","year":"2024","journal-title":"Hematology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.bvth.2024.100019","article-title":"Genetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura","volume":"1","author":"Cao","year":"2024","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_60","first-page":"325","article-title":"Silent cerebral infarction during immune TTP remission: Prevalence, predictors, and impact on cognition","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Takagi, Y., Kobayashi, Y., Hirakata, A., Takei, M., Ogasawara, S., Yajima, C., Ikeuchi, Y., Matsumoto, A., Ogawa, Y., and Handa, H. (2022). Systemic Lupus Erythematosus Presenting with Thrombotic Thrombocytopenic Purpura at Onset: A Case Report. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.931669"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1515\/tjb-2021-0162","article-title":"Prognostic factors in thrombotic thrombocytopenic purpura","volume":"47","author":"Yalciner","year":"2022","journal-title":"Turk. J. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.5045\/br.2022.2022005","article-title":"Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura","volume":"57","author":"Bae","year":"2022","journal-title":"Blood Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Fianchi, L., Bonanni, M., Borchiellini, A., Valeri, F., Giuffrida, G., Grasso, S., Fozza, C., Ponta, M., Tiscia, G.L., and Grandone, E. (2024). Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216561"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Nikolousis, E., Koravou, E.E., Dimou-Besikli, S., Kartsios, C., Papaconstantinou, T., Papathanasiou, M., Syrigou, A., Ztriva, E., and Kaiafa, G. (2023). Caplacizumab for immune thrombotic thrombocytopenic purpura: Real-world multicenter data. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1226114"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/13696998.2021.1992413","article-title":"Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective","volume":"24","author":"Pollissard","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_68","first-page":"43","article-title":"Cost-effectiveness analysis of caplacizumab in the new standard of care of immune thrombotic thrombocytopenic purpura in Italy","volume":"8","author":"Ravasio","year":"2021","journal-title":"Glob. Reg. Health Technol. Assess."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jtha.2024.10.034","article-title":"Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: An Italian multicenter study","volume":"23","author":"Giannotta","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/16078454.2021.1959984","article-title":"Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab","volume":"26","author":"Aggarwal","year":"2021","journal-title":"Hematology"},{"key":"ref_72","first-page":"e17219","article-title":"Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine; a case report","volume":"11","author":"Ghazizadeh","year":"2025","journal-title":"Immunopathol. Persa"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/bjh.19752","article-title":"Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura","volume":"205","author":"Weisinger","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Soares Ferreira Junior, A., Pinheiro Maux Lessa, M., Kaplan, S., Coles, T.M., Terrell, D.R., and Onwuemene, O. (2023). Patient-Reported Outcome Measures in Patients with Thrombotic Thrombocytopenic Purpura: A Systematic Review of the Literature. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155155"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"S\u0103s\u0103ran, M.O., Muntean, C.V., Stoica, A.B., Schwesig, C., V\u0103sie\u0219iu, A.M., Plesca, D.A., and Marginean, O.C. (2025). Clinical and Paraclinical Peculiarities of SARS-CoV-2 and Influenza Infections in Children: A Comparative Study. Life, 15.","DOI":"10.3390\/life15050784"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3892\/etm.2021.10248","article-title":"Review of the measles epidemic in children from Central Eastern Europe in the third millennium","volume":"22","author":"Davitoiu","year":"2021","journal-title":"Exp. Ther. Med."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/3\/350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:29:54Z","timestamp":1772465394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/3\/350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["children13030350"],"URL":"https:\/\/doi.org\/10.3390\/children13030350","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}